Rethinking Remdesivir: Synthesis, Antiviral Activity, and Pharmacokinetics of Oral Lipid Prodrugs

• Published in: Antimicrobial agents and chemotherapy Vol. 65; no. 10; p. e0115521
• Main Authors: Schooley, Robert T, Carlin, Aaron F, Beadle, James R, Valiaeva, Nadejda, Zhang, Xing-Quan, Clark, Alex E, McMillan, Rachel E, Leibel, Sandra L, McVicar, Rachael N, Xie, Jialei, Garretson, Aaron F, Smith, Victoria I, Murphy, Joyce, Hostetler, Karl Y
• Format: Journal Article
• Language: English
• Published: United States American Society for Microbiology 17.09.2021
• Subjects: Adenosine - analogs & derivatives; Adenosine Monophosphate - analogs & derivatives; Alanine - analogs & derivatives; Animals; Antimicrobial Chemotherapy; Antiviral Agents; Antiviral Agents - pharmacology; Caco-2 Cells; COVID-19 Drug Treatment; Cricetinae; Humans; Lipids; Prodrugs; SARS-CoV-2; Huh7.5 cells; PSC-derived human lung cells; Vero E6 cells; SARS-CoV-2; Caco-2 cells; antiviral agents; lipid prodrugs; Calu-3 cells; remdesivir nucleoside; remdesivir

Remdesivir (RDV; GS-5734) is currently the only FDA-approved antiviral drug for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The drug is approved for use in adults or children 12 years or older who are hospitalized for the treatment of COVID-19 on the basi...